On 17 November 2026 the World Health Organization said two vaccine candidates developed specifically for Bundibugyo virus will be added to its Tumaini vaccine trial in the Democratic Republic of the Congo, as the outbreak has more than doubled in three months. The step follows the trial’s launch on 23 October and extends the August prioritisation of Bundibugyo vaccines for trial-only deployment.
What happened
WHO Director-General Tedros Adhanom Ghebreyesus gave the update on 17 November at the third meeting of the International Health Regulations Emergency Committee on Bundibugyo virus disease, according to UN News. He said cases had more than doubled in three months, with more than 11,000 cases and 5,400 deaths reported across 67 health zones in eight provinces, and 400 to 500 new cases still reported each week.
On the vaccines, UN News reports that two candidates developed specifically for Bundibugyo virus will be added to an ongoing vaccine trial in the coming weeks. In a Geneva press conference quoted by AFP, Tedros said: “We expect two candidate vaccines developed specifically for Bundibugyo virus to begin testing as early as next week.”
Key details
The two candidates, as AFP and WHO describe them, are:
- ChAdOx1, an adenoviral vector vaccine developed by the University of Oxford. WHO’s Disease Outbreak News names the Serum Institute of India as a partner on this candidate.
- mRNA-1469, an mRNA vaccine developed by Moderna.
AFP reports that both have completed earlier, smaller Phase 1 trials. WHO’s Disease Outbreak News of 6 November says WHO expert groups recommended adding both candidates and that each will enter the trial only after national approvals. No vaccine or specific treatment is approved for Bundibugyo virus, WHO states.
Tumaini is a platform trial: a single framework that tests the safety, efficacy and immune response of several vaccines. WHO describes it as a Phase 2/3 study that enrolled its first participants in Bunia, in Ituri Province, on 23 October. AFP adds that:
- Ervebo, which is approved for the Zaire species of Ebola virus, began Phase 3 testing in Tumaini on 23 October to see whether it also protects against Bundibugyo;
- the trial uses ring vaccination, immunising high-risk contacts of infected people;
- more than 140 people have enrolled so far, with thousands of contacts expected to join;
- it currently runs at one site in Bunia and is to expand beyond it;
- Meg Doherty, head of WHO’s science for health department, said Phase 2 trials of the two candidates are scheduled to begin on 26 or 27 November in Bunia, and that they would advance to Phase 3 only if Phase 2 safety and immune-response data pass review.
Case counts differ by source and cut-off date, as the table shows.
| Source | Confirmed cases | Deaths | Date or cut-off |
|---|---|---|---|
| WHO Disease Outbreak News (DRC) | 10,668 | 5,198 | As of 3 November 2026 |
| Al Jazeera, citing government data | 11,042 | at least 5,387 | Released 10 November 2026 |
| AFP, citing WHO | 11,376 | 5,568 | Reported 17 November 2026 |
| UN News, WHO Director-General | more than 11,000 | 5,400 | Stated 17 November 2026 |
Background and context
AFP reports that the outbreak was declared in May, triggered an international public health emergency and is the DRC’s worst Ebola outbreak. Al Jazeera, with Reuters, calls it the second-largest and second-deadliest on record, behind the 2014-2016 West African outbreak, which infected more than 28,600 people. It says Bundibugyo kills about half of those it infects, and that delayed detection, conflict and strained health services have let it spread faster than earlier outbreaks. See public health emergency declarations for how these designations work.
WHO’s 6 November report put crude case fatality at 48.7 per cent, with 7,485 cases in Ituri and 2,593 in Nord-Kivu. It records nine confirmed cases and two deaths in Kenya and one imported case in Nigeria, and says contact follow-up averaged 86 per cent against a 95 per cent target. Al Jazeera reports that WHO approved clinical trials of two new vaccines earlier in November and expects results in early 2027.
Reaction
Tedros said children were “paying a terrible price”: they account for more than a quarter of confirmed cases and a third of deaths, and seven in ten children under five with confirmed Ebola have died. He said two-thirds of confirmed deaths occurred outside Ebola treatment centres, which suggests infections are being identified too late, and that the number of laboratories able to test for the virus rose from two to more than two dozen. He warned: “The risk beyond the DRC’s borders is not theoretical,” and “progress in some places is not control of the outbreak as a whole.” He also criticised blanket travel restrictions as hindering the response, a position WHO’s outbreak report repeats.
What it means for researchers, universities and research offices
For vaccine developers, the announcement shows how a platform trial lets candidates enter an existing protocol and site network instead of each starting a separate study. Entry is gated by national approvals and by Phase 2 safety and immune-response review, so timelines depend on regulators and review bodies in the DRC as much as on manufacturing. Teams planning comparable work can read how master protocol designs differ and how data safety monitoring boards and trial phases govern progression between stages.
For funders and research offices, the reported single-site operation and planned expansion mean that site capacity, laboratory testing and community engagement are the working constraints. The rise in testing laboratories from two to more than two dozen is the kind of capacity that sponsored research partners will need to coordinate with. Offices handling outbreak-related sponsored work should expect that the candidates come from an academic developer (Oxford) and an industry developer (Moderna), so agreements will span university, company and WHO-coordinated trial structures. The approach of the Oxford candidate is explained in the guide to viral vector vaccines.
What happens next
Tedros said testing of the two candidates could begin as early as the week after 17 November. Doherty said Phase 2 trials of both candidates are scheduled for 26 or 27 November in Bunia, with Phase 3 only if Phase 2 data pass review. Al Jazeera reports that WHO expects vaccine results in early 2027. The trial is also to expand beyond Bunia, and each new candidate requires national approval before entry.
Sources
- UN News, “Ebola outbreak in DR Congo,” 17 November 2026
- World Health Organization, Disease Outbreak News: Bundibugyo virus disease, DRC, Kenya and Nigeria, 6 November 2026
- AFP via Yahoo News, strain-specific Ebola vaccine trials, 17 November 2026
- Al Jazeera with Reuters, “Ebola cases in DR Congo pass 11,000 with 5,387 deaths,” 11 November 2026







